Novel Agent Shows Early Activity in Phase 2 Recurrent Thymoma Study
Treatment with PT-112 appeared to be well-tolerated among those with recurrent thymoma in a phase 2 trial.
Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care
Daniel C. McFarland, DO; and Michelle B. Riba, MD, spoke about distress screening and integrating psychosocial care into oncology.
Sacituzumab Govitecan Yields Fewer AEs Vs Chemotherapy in Advanced TNBC
Safety data from ASCENT-03 support sacituzumab govitecan as an effective therapy with manageable toxicities in advanced triple-negative breast cancer.
ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia
Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.
Zanubrutinib Therapies Yield Durable Results in High-Risk, Treatment-Naïve CLL/SLL
Results from arms C and D of the phase 3 SEQUOIA trial demonstrated that zanubrutinib alone or in combination with venetoclax yields positive results in CLL/SLL subpopulations.
Breast Cancer Data Affirm Aromatase Inhibitors as Optimal Endocrine Therapy
Exploratory data from a phase 3 study may help optimize adjuvant endocrine therapy choices in hormone receptor–positive, HER2-positive breast cancer.
